RNA
Avidity Biosciences Inc
NASDAQ · Biotechnology
$72.90
+0.08 (+0.11%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 14.73M | 13.99M | 2.64B | 2.36B | 2.44B |
| Net Income | -435,440,146 | -372,135,724 | -726,828,585 | -651,372,475 | -517,686,100 |
| EPS | — | — | — | — | — |
| Profit Margin | -2,957.7% | -2,809.8% | -27.5% | -27.6% | -21.2% |
| Rev Growth | +5.3% | +5.3% | +2.7% | +6.9% | +24.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 3.17B | 2.58B | 3.15B |
| Total Equity | — | — | 5.14B | 5.59B | 5.69B |
| D/E Ratio | — | — | 0.62 | 0.46 | 0.55 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -508,538,615 | -458,751,955 | -980,937,033 | -865,943,607 | -944,563,645 |
| Free Cash Flow | — | — | -510,766,902 | -400,975,764 | -475,814,962 |